Halozyme CEO Helen Torley
March 29, 2022 02:07 PM EDTUpdated March 31, 10:25 AM
Deals

Roche's Chugai lines up a $185M deal to switch drug can­di­date to sub­cu­ta­neous for­mu­la­tion

John Carroll

Editor & Founder

Back in the spring of 2020, J&J and its part­ner on the big mul­ti­ple myelo­ma drug Darza­lex an­nounced a big im­prove­ment for the pro­gram af­ter …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

A service from the Financial Times